Overview
Law360 quoted John Molenda in an article titled “Biologic Fights Drive PTAB Drug Challenges to Record High.” The article, published February 8, discusses how the number of challenges to drug patents at the Patent Trial and Appeal Board (PTAB) climbed to a record high in 2017, bolstered by an increasing number of petitions targeting patents covering biologics. Attorneys say that growth reflects the increasing importance of biologics, and part of it might simply be a matter of timing.
Dr. Molenda says: “What we’re seeing in the biosimilars space is that a number of potential biosimilar applicants appear to be in the late stages of their development programs. As a consequence of that, they feel the need to clear the patent thicket by filing IPRs.”
The full article can be read at Law360 (subscription required).
